

Expert viewpoints: outlook for nosocomial infections

- ① *“But, whether they’re [Federal Government] correct or not, one of the things that they’ve stated is going to be, as of October 2008, they’re not paying for catheter related bloodstream infections anymore, they said if you have it, it’s 100% preventable, and, therefore, we won’t pay for it. Ventilator-associated Pneumonia (VAP) is on, I think, next year’s list, and so the incidence for that will go down as well, people will pay attention to the sort of things that they can do, have the bed up, oral care, etc” – US opinion leader*
- ① *“If I have to do a dynamic prospective over the next three to five years, I think that probably the scenario will be worse than now, for sure, especially for gram-negatives because we don’t have any new antibiotics active against these resistant strains, no new antibiotics in gram-negatives. Of course we have many new antibiotics active against gram-positive, like MRSA, but probably in the next case three to five years the scenario in my opinion will be worse than now.” – Italy opinion leader*
- ① *“The MRSA bacteraemia rate, at least, seems to be falling slightly. Mostly I would say through very heavy efforts on infection control. However, if one looks at gram-negatives, problems are increasing, Coli and Klebsiella in particular are becoming more multi-resistant and particularly they’re becoming significantly more resistant to quinolones and cephalosporins. Those are trends that pertain across much of Europe, if you look at the ESBL website, not just in the United Kingdom.”– UK opinion leader*



About VacZine Analytics:

VacZine Analytics is a brand new research consultancy based in the United Kingdom. Its aim is to provide high-quality disease and commercial analysis to those working within or in collaboration with the vaccine and biologics industry.

With our product lines:

- ① DiseaseINFOPACK
- ① OpportunitySCAN
- ① MarketVIEW
- ① ExpertREACT

Our key focus is helping clients to build the case for developing new vaccines.

Disclaimer

All rights reserved

This licensed product (or part thereof) may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the publisher VacZine Analytics (a division of Assay Advantage Ltd).

The facts presented within this document, at the time of its production, were believed to be correct and were gathered in good faith from both primary and secondary sources. VacZine Analytics is not always in the position to assure that the facts are guaranteed. VacZine Analytics cannot be held liable for any actions based upon facts or recommendations presented within this document.



VacZine Analytics

Bringing life to vaccine strategy...

www.vacZine-analytics.com

Warren House

Bells Hill

Bishops Stortford

Herts

CM23 2NN

United Kingdom

Tel. +44 (0) 1279 654514

e-mail: info@vacZine-analytics.com

© VacZine Analytics, 2007. All rights reserved.